[Opinion] Should the 90% CI for GMR be required to encompass 1 [RSABE / ABEL]

posted by jag009  – NJ, 2018-03-29 19:55 (1307 d 09:09 ago) – Posting: # 18619
Views: 8,406

Hi,

» Actually, I am questioning the validity of FDA's Swr scaled 10% window on BE for NTID.
»
» If a GMR of 1.1 is clinically relevant (i.e. a test should be sensitive for this), and the NTID with a Swr of .22 will pass by ABE, this is a failure IMO.

Before we go further, does your hypothetical example pass the other two criteria stated in the NTI guidance?

Complete thread:

Activity
 Admin contact
21,758 posts in 4,550 threads, 1,544 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Wednesday 05:05 CEST (Europe/Vienna)

There ain’t no rules around here!
We’re trying to accomplish something!    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5